Plus Therapeutics
Quarterly Financials
| Values in thousands | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 |
|---|---|---|---|---|
Revenue | $0 | $1,279 | $1,677 | $1,313 |
Gross Profit | -1,494 | 1,491 | 1,131 | |
EBITDA | -2,581 | -2,711 | -3,041 | -3,568 |
EBIT | -2,813 | -2,913 | -3,227 | -3,750 |
Net Income | -2,874 | -2,940 | -3,261 | -3,810 |
Net Change In Cash | 0 | 1,279 | 1,677 | 1,313 |
Free Cash Flow | -3,694 | -1,776 | -4,553 | -1,923 |
Cash | 1,223 | 4,912 | 2,901 | 8,554 |
Basic Shares | 7,855 | 10,742 | 4,321 | 4,522 |
Annual Financials
| Values in thousands | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
|---|---|---|---|---|
Revenue | $4,913 | $224 | $0 | $303 |
Gross Profit | -4,777 | -488 | -66 | -2,397 |
EBITDA | -12,693 | -18,852 | -12,492 | -6,765 |
EBIT | -13,321 | -19,564 | -12,911 | -7,134 |
Net Income | -13,316 | -20,838 | -14,331 | -9,348 |
Net Change In Cash | 4,913 | 224 | 0 | 303 |
Cost of Revenue | -9,246 | |||
Free Cash Flow | -13,011 | -13,481 | -10,424 | -8,927 |
Cash | 8,554 | 18,120 | 18,400 | 8,346 |
Basic Shares | 3,140 | 1,750 | 805 | 295 |
Earnings Calls
| Quarter | EPS |
|---|---|
2024-09-30 | -$0.37 |
2024-06-30 | -$0.56 |
2024-03-31 | -$0.75 |
2023-12-31 | -$0.84 |
